Due to COVID-19, new study enrollment is being assessed on a case by case basis. If you have any questions please call our central phone number at 616-391-1230.

All Open Clinical Trials

Brain/CNS

Protocol Alliance A071601
Cancer Type: CRANIOPHARYNGIOMAS
Fast Facts

Phase II Trial of BRAF/MEK Inhibitors in Papillary Craniopharyngiomas

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A071702
Cancer Type: Recurrent Glioblastoma
Fast Facts

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients with Somatically Hypermutated Recurrent Glioblastoma

Protocol NRG BN007
Cancer Type: Unmethylated Glioblastoma
Fast Facts

A Randomized Phase II/III Open-Label Study of Ipilimumab and Nivolumab Versus Temozolomide in Patients With Newly Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma

Protocol NRG BN011
Cancer Type: Methylated MGMT Promoter Glioblastoma
Fast Facts

A Phase III Trial of Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Patients with Methylated MGMT Promoter Glioblastoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol N0577
Cancer Type: Codeleted Anaplastic Glioma
Fast Facts

Phase III Intergroup Study of Radiotherapy versus Temozolomide Alone versus Radiotherapy with Concomitant and Adjuvant Temozolomide for Patients with 1p/19q Codeleted Anaplastic Glioma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A071401
Cancer Type: MENINGIOMAS WITH SMO/AKT/NF2 MUTATIONS
Fast Facts

PHASE II TRIAL OF SMO/AKT/NF2/CDK INHIBITORS IN PROGRESSIVE MENINGIOMAS WITH SMO/AKT/NF2/CDK PATHWAY MUTATIONS

Protocol NRG BN003
Cancer Type: MENINGIOMA
Fast Facts

Phase III Trial of Observation Versus Irradiation for a Gross Totally Resected Grade II Meningioma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A071701
Cancer Type: Brain metastases
Fast Facts

Genomically-Guided Treatment Trial in Brain Metastases

Please check out the rare protocol list to locate other studies within this disease site.

Protocol WF 1801
Cancer Type: Cancer Control
Fast Facts

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG ACNS1422
Cancer Type: Medulloblastoma
Fast Facts

A Phase II Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Age - Patients must be Greater than or Equal to 3 Years and Less than 22 Years of Age at the Time of Enrollment on ACNS1422 Step 0.

Protocol COG ACNS1723
Cancer Type: High-Grade Glioma
Fast Facts

A Phase II Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAFV600-Mutant High-Grade Glioma (HGG) (IND# 145355)

Patients must be ≥ 3 Years and ≤ 25 Years of Age at the Time of Enrollment on Step 0.

Note: The HGG Pre-Enrollment Eligibility Screening (Step 0) has been paused until further notice.

Protocol COG ACNS1831
Cancer Type: Low-Grade Glioma
Fast Facts

A Phase III Randomized Study of Selumetinib (IND # 77782) versus Carboplatin/Vincristine in 
Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Patients must be ≥ 2 Years and ≤ 21 Years at the Time of Enrollment.

Protocol COG ACNS1833
Cancer Type: Low-Grade Glioma
Fast Facts

ACNS1833: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)

Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment on ACNS1833 Step 0.

Protocol COG ANBL00B1
Cancer Type: Neuroblastoma-Biology
Fast Facts

Neuroblastoma Biology Studies

All Newly Diagnosed Patients with Suspected Neuroblastoma, Suspected Ganglioneuroblastoma, or Suspected Ganglioneuroma/Maturing Subtype Seen at COG Institutions are Eligible for this Study. 

Protocol COG ACNS1931
Cancer Type: Low Grade Glioma
Fast Facts

COG-ACNS1931: A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Feasibility Phase - Patients must be ≥ 2 years and ≤ 21 years of age at the time of enrollment.
Efficacy Phase: Patients must be ≥ 2 years and ≤ 25 years of age at the time of enrollment.
All patients > 21 years of age at the time of enrollment must have had initial diagnosis of low-grade glioma by 21 years of age.

Protocol COG ACNS2021
Cancer Type: CNS - Germ Cell
Fast Facts

COG ACNS2021

A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

Patients must be greater than or equal to 3 years and less than 30 years at the time of study enrollment.

Protocol COG ACNS1821
Cancer Type: CNS - DIPG & HGG
Fast Facts

COG ACNS1821: A Phase 1/2 Trial of Selinexor (KPT-330) and Radiation Therapy in Newly-Diagnosed Pediatric Diffuse Intrinsic Pontine Glioma (DIPG) and High-Grade Glioma (HGG)

Patients must be ≥ 12 months and ≤ 21 years of age at the time of enrollment.

Protocol COG ACCL2031
Cancer Type: CNS
Fast Facts

COG ACCL2031

A Phase 3 Randomized, Placebo-Controlled Trial Evaluating Memantine (IND# 149832) for Neurocognitive Protection in Children Undergoing Cranial Radiotherapy as Part of Treatment for Primary Central Nervous System Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Breast

Protocol EA1181
Cancer Type: Neoadjuvant Breast
Fast Facts

Preoperative THP and postoperative HP in patients who achieve a pathologic complete response

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1706
Cancer Type: Inflammatory Breast Cancer

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Protocol Alliance A011801
Cancer Type: HER2 positive Breast Cancer
Fast Facts

The COMPASSHER2 Trials (COMprehensive Use of Pathologic Response ASSessment to Optimize Therapy in HER2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib

Please check out the rare protocol list to locate other studies within this disease site.

Protocol CCTG MA.39 Adjuvant
Cancer Type: LOW RISK NODE POSITIVE BREAST CANCER
Fast Facts

TAILOR RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

Protocol NRG BR007
Cancer Type: Stage 1, Hormone Sensitive Her2 negative
Fast Facts

Phase III Clinical Trial Evaluating De-Escalation of Breast Radiation for Conservative Treatment of Stage 1, Hormone Sensitive HER2-Negative, Oncotype Recurrence Score < 18 Breast Cancer (DEBRA) De-Escalation of Breast Radiation

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S2007
Cancer Type: HER2-Negative Breast Cancer
Fast Facts

 A Phase II Trial of Sacituzumab Govitecan for Patients with HER2-Negative Breast Cancer and Brain Metastases

Please check out the rare protocol list to locate other studies within this disease site.

Protocol AFT-25 COMET
Cancer Type: Low Risk DCIS
Fast Facts

Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low Risk DCIS: A Phase III Prospective Randomized Trial

 

Please check out the rare protocol list to locate other studies within this disease site.

Protocol PDM 9846
Cancer Type: Tissue Procurement
Fast Facts

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1501 CC cardiac tox
Cancer Type: METASTATIC HER-2+ BREAST CANCER
Fast Facts

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III

Protocol SWOG S1703
Cancer Type: METASTATIC BREAST CANCER
Fast Facts

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer

Protocol URCC 16070 CC nausea
Cancer Type: Cancer Control
Fast Facts

Treatment of Refractory Nausea

Protocol Alliance A231901CD
Cancer Type: CCDR
Fast Facts

IMPROVING PATIENT-CENTERED COMMUNICATION IN BREAST CANCER: A RCT OF A SHARED DECISION ENGAGEMENT SYSTEM (SHARES)

Protocol Alliance A191901
Cancer Type: Cancer Control
Fast Facts

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA1151 (TMIST)
Cancer Type: Screening
Fast Facts

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Please check out the rare protocol list to locate other studies within this disease site.

Cancer Care Delivery (CCDR)

Protocol Alliance A231901CD
Cancer Type: CCDR
Fast Facts

IMPROVING PATIENT-CENTERED COMMUNICATION IN BREAST CANCER: A RCT OF A SHARED DECISION ENGAGEMENT SYSTEM (SHARES)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1912CD
Cancer Type: CCDR
Fast Facts

A RANDOMIZED TRIAL ADDRESSING CANCER-RELATED FINANCIAL HARDSHIP THROUGH
DELIVERY OF A PROACTIVE FINANCIAL NAVIGATION INTERVENTION (CREDIT)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG ACCL20N1CD
Cancer Type: ALL
Fast Facts

COG ACCL20N1CD: Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States

Please check out the rare protocol list to locate other studies within this disease site.

Cancer Control

Protocol Alliance A212102
Cancer Type: Early Detection Blood Tests
Fast Facts

Blinded Reference Set for Multicancer Early Detection Blood Tests

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S2001
Cancer Type: Metastatic Pancreatic
Fast Facts

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations.

Please check out the rare protocol list to locate other studies within this disease site.

Protocol PDM 9846
Cancer Type: Tissue Procurement
Fast Facts

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol WF 1801
Cancer Type: Cancer Control
Fast Facts

A Single Arm, Pilot Study of Ramipril for Preventing Radiation-Induced Cognitive Decline in Glioblastoma (GBM) Patients Receiving Brain Radiotherapy

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1501 CC cardiac tox
Cancer Type: METASTATIC HER-2+ BREAST CANCER
Fast Facts

Prospective Evaluation of Carvedilol in Prevention of Cardiac Toxicity in Patients With Metastatic HER-2+ Breast Cancer, Phase III

Protocol SWOG S1703
Cancer Type: METASTATIC BREAST CANCER
Fast Facts

Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored With Serum Tumor Marker Directed Disease Monitoring (STMDDM) Versus Usual Care in Patients With Metastatic Hormone Receptor Positive HER-2 Negative Breast Cancer

Protocol URCC 16070 CC nausea
Cancer Type: Cancer Control
Fast Facts

Treatment of Refractory Nausea

Protocol SWOG S1904
Cancer Type: ATYPICAL HYPERPLASIA OR LOBULAR CARCINOMA IN SITU
Fast Facts

CLUSTER RANDOMIZED CONTROLLED TRIAL OF PATIENT AND PROVIDER DECISION SUPPORT TO INCREASE CHEMOPREVENTION INFORMED CHOICE AMONG WOMEN WITH
ATYPICAL HYPERPLASIA OR LOBULAR CARCINOMA IN SITU - MAKING INFORMED CHOICES ON INCORPORATING CHEMOPREVENTION INTO CARE (MiCHOICE)

Protocol Alliance A191901
Cancer Type: Cancer Control
Fast Facts

Optimizing Endocrine Therapy Through Motivational Interviewing and Text Interventions

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S0820
Cancer Type: Colorectal
Fast Facts

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)

Protocol WF 1806
Cancer Type: Cancer Control
Fast Facts

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study

Protocol Alliance A221805
Cancer Type: CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY
Fast Facts

DULOXETINE TO PREVENT OXALIPLATIN-INDUCED CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TO PHASE III STUDY

Please check out the rare protocol list to locate other studies within this disease site.

Protocol WF 1802
Cancer Type: Prostate Cancer
Fast Facts

Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EAQ172
Cancer Type: Pneumonitis
Fast Facts

Optimizing Immunosuppression for Steroid-Refractory Anti-PD-1/PD-L1 Pneumonitis

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A211901
Cancer Type: Rural Cancer Survivors
Fast Facts

REACHING RURAL CANCER SURVIVORS WHO SMOKE USING TEXT-BASED CESSATION INTERVENTIONS

Protocol URCC 21038
Cancer Type: Cancer Survivors
Fast Facts

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

Protocol URCC 18007
Cancer Type: Cancer-Related Fatigue
Fast Facts

Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA1151 (TMIST)
Cancer Type: Screening
Fast Facts

Tomosynthesis Mammographic Imaging Screening Trial (TMIST)

Protocol EA2185
Cancer Type: Pancreatic Cyst Surveillance
Fast Facts

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

Protocol DCP-001
Cancer Type: Multisite - Screening

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Protocol NRG CC005 FORTE
Cancer Type: Colonoscopy
Fast Facts

FORTE (Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps)

Protocol EAQ201
Cancer Type: Decline TMIST participation
Fast Facts

COVID-19 Related Financial Hardship and Distress in Women Who Decline TMIST (EA1151) Participation

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG ALTE03N1
Cancer Type: Multi-site Cancer Control
Fast Facts

Key Adverse Events After Childhood Cancer

Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.

Protocol COG ALTE07C1
Cancer Type: Multi-Site Cancer Control
Fast Facts

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Please check out the rare protocol list to locate other studies within this disease site.

Endocrine/Neuroendocrine

Protocol Alliance A021602
Cancer Type: Neuroendocrine
Fast Facts

RANDOMIZED, DOUBLE-BLINDED PHASE III STUDY OF CABOZANTINIB VERSUS PLACEBO IN PATIENTS WITH ADVANCED NEUROENDOCRINE TUMORS AFTER PROGRESSION ON PRIOR THERAPY (CABINET)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A021804
Cancer Type: ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

Please check out the rare protocol list to locate other studies within this disease site.

Gastrointestinal

Protocol NRG GI005
Cancer Type: Stage IIA Colon Cancer
Fast Facts

Phase II/III Study of Circulating tumOr DNA as a Predictive BiomaRker in Adjuvant Chemotherapy in Patients with Stage IIA Colon Cancer (COBRA)

Protocol Alliance A021502
Cancer Type: Colon Cancer
Fast Facts

Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (ATOMIC: Adjuvant Trial of Deficient Mismatch Repair in Colon Cancer)

Protocol NRG GI008
Cancer Type: Colon Adjuvant
Fast Facts

COLON ADJUVANT CHEMOTHERAPY BASED ON EVALUATION OF RESIDUAL DISEASE (CIRCULATE-US)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA2186
Cancer Type: Metastatic Pancreatic
Fast Facts

A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)

Protocol SWOG S2001
Cancer Type: Metastatic Pancreatic
Fast Facts

Randomized Phase II Clinical Trial of Olaparib + Pembrolizumab vs. Olaparib Alone as Maintenance Therapy in Metastatic Pancreatic Cancer Patients with Germline BRCA1 or BRCA2 Mutations.

Protocol Alliance A021806
Cancer Type: RESECTABLE PANCREATIC CANCER
Fast Facts

A PHASE III TRIAL OF PERIOPERATIVE VERSUS ADJUVANT CHEMOTHERAPY FOR RESECTABLE PANCREATIC CANCER

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1922
Cancer Type: Small bowel Adenocarcinoma

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA2176
Cancer Type: treatment-naïve metastatic anal cancer
Fast Facts

A Phase III Study of Immune checkpoint inhibition with chemotherapy in treatment-naïve metastatic anal cancer patients

Protocol EA2182
Cancer Type: Early Stage Anal Squamous Cell Carcinoma
Fast Facts

A Randomized Phase II Study of De-intensified Chemoradiation for Early Stage Anal Squamous Cell Carcinoma (DECREASE)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA2187
Cancer Type: Advanced Intrahepatic Cholangiocarinoma
Fast Facts

A Phase II Study of Pevonedistat in Combination with Carboplatin and Paclitaxel in Advanced Intrahepatic Cholangiocarcinoma

Protocol EA2197
Cancer Type: Incidental Gallbladder Cancer
Fast Facts

Optimal Perioperative Therapy for Incidental Gallbladder Cancer (OPT-IN)- A Randomized Phase II/III Trial

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A021703
Cancer Type: metastatic colorectal cancer
Fast Facts

Randomized Double-Blind Phase III Trial of Vitamin D3 Supplementation in Patients with Previously Untreated Metastatic Colorectal Cancer (SOLARIS)

Protocol NRG GI004
Cancer Type: Colorectal Cancer
Fast Facts

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A Randomized Phase III Study of mFOLFOX6/Bevacizumab Combination Chemotherapy with or without Atezolizumab or Atezolizumab Monotherapy in the First-Line Treatment of Patients with Deficient DNA Mismatch Repair (dMMR) Metastatic Colorectal Cancer

Protocol SWOG S2107
Cancer Type: Metastatic Colorectal
Fast Facts

Randomized Phase II trial of encorafenib and cetuximab with or without nivolumab (NSC #748726) for patients with previously treated, microsatellite stable, BRAFV600E metastatic and/or unresectable colorectal cancer

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA2183
Cancer Type: Esophageal and Gastric Adenocarcinoma
Fast Facts

A Phase III Study of Consolidative Radiotherapy in Patients with Oligometastatic Esophageal and Gastric Adenocarcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol PDM 9846
Cancer Type: Tissue Procurement
Fast Facts

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S0820
Cancer Type: Colorectal
Fast Facts

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon or Rectal Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)

Protocol WF 1806
Cancer Type: Cancer Control
Fast Facts

Myopenia and Mechanisms of Chemotherapy Toxicity in Older Adults with Colorectal Cancer: The M&M Study

Protocol Alliance A221805
Cancer Type: CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY
Fast Facts

DULOXETINE TO PREVENT OXALIPLATIN-INDUCED CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE II TO PHASE III STUDY

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA2185
Cancer Type: Pancreatic Cyst Surveillance
Fast Facts

Comparing the Clinical Impact of Pancreatic Cyst Surveillance Programs

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG AHEP1531
Cancer Type: PHITT
Fast Facts

Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT)

Age: Patients must be ≤ 30 Years of Age at the Time of Diagnosis

As of June 30, 2022, AHEP1531 Group D is temporarily closed to accrual.

Please check out the rare protocol list to locate other studies within this disease site.

Genitourinary

Protocol SWOG S1802
Cancer Type: Metastatic Prostate Cancer
Fast Facts

Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer

Protocol EA8171
Cancer Type: Prostate Cancer
Fast Facts

Multiparametric MRI (mpMRI) for Preoperative Staging and Treatment Planning for Newly-Diagnosed Prostate Cancer

Protocol NRG GU009
Cancer Type: HIGH RISK PROSTATE CANCER
Fast Facts

PARALLEL PHASE III RANDOMIZED TRIALS FOR HIGH RISK PROSTATE CANCER EVALUATING DE-INTENSIFICATION FOR LOWER GENOMIC RISK AND INTENSIFICATION OF CONCURRENT THERAPY FOR HIGHER GENOMIC RISK WITH RADIATION (PREDICT-RT*)

Protocol NRG GU010
Cancer Type: Prostate Cancer
Fast Facts

NRG-GU010 - Parallel Phase III Randomized Trials of Genomic Risk Stratified Unfavorable Intermediate Risk Prostate Cancer: De-Intensification and Intensification Clinical Trial Evaluation (GUIDANCE)

Protocol Alliance A031902
Cancer Type: Prostate Cancer
Fast Facts

A PHASE III TRIAL OF ENZALUTAMIDE AND RUCAPARIB AS A NOVEL THERAPY IN FIRST-LINE METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A031704
Cancer Type: METASTATIC UNTREATED RENAL CELL
Fast Facts

PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib with Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell Cancer [PDIGREE]

Protocol SWOG S1931
Cancer Type: METASTATIC RENAL CELL CARCINOMA
Fast Facts

PHASE III TRIAL OF IMMUNOTHERAPY-BASED DRUG COMBINATION THERAPY WITH OR WITHOUT CYTOREDUCTIVE NEPHRECTOMY FOR METASTATIC RENAL CELL CARCINOMA (PROBE TRIAL)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A031803
Cancer Type: BCG-Unresponsive Non Muscle Invasive Bladder
Fast Facts

Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

Protocol SWOG S1806
Cancer Type: Bladder Cancer
Fast Facts

Phase III Randomized Trial of Concurrent Chemoradiotherapy With or Without Atezolizumab In Localized Muscle Invasive Bladder Cancer 

Protocol SWOG S1937
Cancer Type: Metastatic Urothelial Carcinoma
Fast Facts

A Phase III Randomized Trial of Eribulin (NSC #707389) with or without Gemcitabine versus Standard of Care (Physician’s Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A031702
Cancer Type: rare genitourinary tumors

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1823
Cancer Type: Newly Diagnosed Germ Cell Tumors
Fast Facts

A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Protocol WF 1802
Cancer Type: Prostate Cancer
Fast Facts

Influence of Primary Treatment for Prostate Cancer on Work Experience (PCW)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG AREN03B2
Cancer Type: Renal-Biology
Fast Facts

Renal Tumors Classification, Biology, and Banking Study 

Patients must be < 30 Years Old at the Time of Diagnosis

Protocol COG AREN1921
Cancer Type: Wilms
Fast Facts

COG-AREN1921: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Patients must be ≤ 30 years old at study enrollment.

Please check out the rare protocol list to locate other studies within this disease site.

Germ Cell

Protocol COG AGCT1531
Cancer Type: Germ Cell
Fast Facts

A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Age:

Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
Patients must be < 50 Years of Age at Enrollment.

Standard Risk 1
Patient must be < 11 Years of Age at Enrollment.

Standard Risk 2 & AYA-HEARS
Patients must be ≥ 11 and < 25 Years of Age at Enrollment. 

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1823
Cancer Type: Newly Diagnosed Germ Cell Tumors
Fast Facts

A Prospective Observational Cohort Study to Assess miRNA 371 for Outcome Prediction in Patients With Newly Diagnosed Germ Cell Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG ACNS2021
Cancer Type: CNS - Germ Cell
Fast Facts

COG ACNS2021

A Phase 2 Trial of Chemotherapy followed by Response-Based Whole Ventricular & Spinal Canal Irradiation (WVSCI) for Patients with Localized Non-Germinomatous Central Nervous System Germ Cell Tumor

Patients must be greater than or equal to 3 years and less than 30 years at the time of study enrollment.

Protocol COG AGCT1532
Cancer Type: Germ Cell
Fast Facts

Phase III Accelerated BEP: A Randomised Phase 3 Trial of Accelerated Versus Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours

Age ≥ 11 Years and ≤ 45 Years on the Date of Randomization

Please check out the rare protocol list to locate other studies within this disease site.

Gynecologic

Protocol NRG CC008
Cancer Type: Ovarian Cancer Among BRCA1 Carriers
Fast Facts

A Non-Randomized Prospective Clinical Trial Comparing the Non-Inferiority of Salpingectomy to Salpingo-oophorectomy to Reduce the Risk of Ovarian Cancer Among BRCA1 Carriers [SOROCk] 

Protocol NRG GY019
Cancer Type: Carcinoma of the Ovary or Peritoneum
Fast Facts

A Randomized Phase III, Two-Arm Trial of Paclitaxel/Carboplatin/Maintenance Letrozole Versus Letrozole Monotherapy in Patients with Stage II-IV, Primary Low-Grade Serous Carcinoma of the Ovary or Peritoneum

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG GY018
Cancer Type: ENDOMETRIAL CANCER
Fast Facts

A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer

Protocol NRG GY026
Cancer Type: Endometrial serous carcinoma or carcinosarcoma
Fast Facts

A Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk (HERCEPTIN HYLECTA) or pertuzumab trastuzumab and hyaluronidase-zzfx (PHESGO) in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG GY024
Cancer Type: Vulvar Cancer
Fast Facts

Groningen International Study on Sentinel Nodes in Vulvar Cancer III (GROINSS-V III), a prospective phase II treatment trial

Please check out the rare protocol list to locate other studies within this disease site.

Head and Neck

Protocol EA3132
Cancer Type: Head and Neck
Fast Facts

Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing    

Protocol EA3161
Cancer Type: HPV Positive OPCA
Fast Facts

A Phase II/III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPCA

Protocol NRG HN005
Cancer Type: Oropharyngeal Cancer
Fast Facts

A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer

Protocol RTOG 1216
Cancer Type: Pathologic High-Risk Squamous Cell Cancer
Fast Facts

Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

Protocol EA3163
Cancer Type: Nasal and Paranasal Sinus Squamous Cell Carcinoma

Phase II Randomized Trial of Neo-Adjuvant Chemo f/b Surgery and Post-Op Radiation vs Surgery and Post-Op Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG HN001
Cancer Type: Nasopharyngeal Carcinoma

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Please check out the rare protocol list to locate other studies within this disease site.

Leukemia

Protocol Alliance A041501
Cancer Type: NEWLY DIAGNOSED PRECURSOR B-CELL ALL
Fast Facts

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) With Newly Diagnosed Precursor B-Cell ALL

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG ADVL1823
Cancer Type: multisite
Fast Facts

COG-ADVL1823: Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Patients must be ≤ 30 years of age at the time of study entry

Temporarily Closed to Accrual

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A041701
Cancer Type: ACUTE MYELOID LEUKEMIA
Fast Facts

A Randomized Phase II/III Study of Conventional Chemotherapy +/- Uproleselan (GMI-1271) in Older Adults With Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1925
Cancer Type: CLL/SLL
Fast Facts

RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NHLBI-MDS
Cancer Type: Myelodysplastic Syndromes
Fast Facts

The National Myelodysplastic Syndromes (MDS) Study

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG AALL15P1
Cancer Type: Acute Lymphoblastic Leukemia (ALL)
Fast Facts

A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants With Acute Lymphoblastic Leukemia (ALL) and KMT2A (MLL) Gene Rearrangement

Infants Less than 1 Year of Age on the Date of Diagnosis are Eligible; Infants must be >36 Weeks Gestational Age at the Time of Enrollment.

Protocol COG ACCL20N1CD
Cancer Type: ALL
Fast Facts

COG ACCL20N1CD: Financial Distress during Treatment for Pediatric Acute Lymphoblastic Leukemia in the United States

Protocol COG AALL1621
Cancer Type: Relapsed Refractory CD22 B-ALL
Fast Facts

A Phase II Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Patients must be ≥1 Year and < 22 Years of Age at the Time of Enrollment.

AALL1621 has been temporarily closed to accrual as of March 8, 2022, pending an evaluation of patients currently enrolled on this study.

Protocol COG AALL1521
Cancer Type: Acute Lymphoblastic Leukemia (ALL)
Fast Facts

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

Age ≥ 1 Year and ≤ 21 Years at Time of Leukemia Diagnosis.

Protocol COG AALL1631
Cancer Type: Ph+ ALL
Fast Facts

International Phase III Trial in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Testing Imatinib in Combination With Two Different Cytotoxic Chemotherapy Backbones

Age:  > 1 Year and < 21 Years at ALL Diagnosis

Protocol COG AALL1731
Cancer Type: B-ALL, B-LLy
Fast Facts

A Phase III Trial Investigating Blinatumomab (IND# 117467, NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Patients must be ≥ 365 Days and < 10 Years of Age (B-ALL Patients without DS)

Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-ALL Patients with DS)

Patients must be ≥ 365 Days and ≤ 31 Years of Age (B-LLy Patients with or without DS

Temporary Partial Closure to Accrual of Down syndrome High-Risk B-ALL arm

Protocol COG AALL1732
Cancer Type: B-ALL, B-LLy
Fast Facts

A Phase III Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518)for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL,Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Patients must be > 365 Days and < 25 Years of Age

Protocol COG AALL1821
Cancer Type: B-ALL
Fast Facts

COG AALL1821

A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC# 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged >/=1 to <31 Years Old with First Relapse

Group 1 is permanently closed to accrual. The Down syndrome arm remains open to accrual. Accrual for Group 2 and Group 3 remains temporarily closed.

Protocol COG AAML18P1
Cancer Type: Chronic Myeloid Leukemia
Fast Facts

COG AAML18P1

Stopping Tyrosine Kinase Inhibitors (TKI) to Assess Treatment-Free Remission (TFR) in Pediatric Chronic Myeloid Leukemia - Chronic Phase (CML-CP)

Patient must have been diagnosed with CML-CP at less than 18 years of age

Patient mustbe less than 25 years of age at enrollment

Protocol COG AAML1831
Cancer Type: de nova AML
Fast Facts

COG-AAML1831: A phase 3 randomized trial for patients with de novo AML comparing standard therapy including gemtuzumab ozogamicin GO to CPX-351 with GO, and the addition of the FLT3 inhibitor gilteritinib for patients with FLT3 mutations

Patients must be less than 22 years of age at the time of study enrollment.

As of June 14th, 2022, Arms C and D (AC, BC, AD, BD) in protocol AAML1831 are temporarily closed to accrual

Protocol COG APAL2020SC
Cancer Type: Relapsed Leukemia
Fast Facts

COG APAL2020SC

Pediatric Acute Leukemia (PedAL) Screening Trial – Developing New Therapies for Relapsed Leukemias

Patients must be less than 22 years of age at the time of study enrollment.

Please check out the rare protocol list to locate other studies within this disease site.

Lung

Protocol ECOG E4512
Cancer Type: Non-Small Cell Lung
Fast Facts

A Randomized Phase III Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Observation for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

A substudy of ALCHEMIST A151216

Protocol EA5162
Cancer Type: Advanced NSCLC
Fast Facts

Phase II Study of AZD9291 (Osimertinib) in Advanced NSCLC Patients with Exon 20 Insertion Mutations in EGFR

Protocol EA5163
Cancer Type: Non-Small Cell Lung Cancer (NSCLC)
Fast Facts

A Randomized, Phase III Study of Firstline Immunotherapy alone or in Combination with Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Immunobiomarker SIGNature-driven Analysis

Protocol EA5181
Cancer Type: NSCLC
Fast Facts

Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC

Protocol NRG LU002
Cancer Type: METASTATIC NON-SMALL CELL LUNG CANCER
Fast Facts

Maintenance Systemic Therapy Versus Local Consolidative Therapy (LCT) Plus Maintenance Systemic Therapy for Limited Metastatic Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II/III Trial

Protocol SWOG S1914
Cancer Type: Early Stage NSCLC
Fast Facts

A Randomized Phase III Trial of Induction/Consolidation Atezolizumab (NSC #783608) + SBRT Versus SBRT Alone in High Risk, Early Stage NSCLC

Protocol Alliance A081801
Cancer Type: resected NSCLC
Fast Facts

Integration of immunotherapy into adjuvant therapy for resected NSCLC: ALCHEMIST chemo-IO

Protocol EA5191
Cancer Type: NSCLC
Fast Facts

 A Randomized Phase II Trial of Cabozantinib and Cabozantinib Plus Nivolumab Versus Standard Chemotherapy in Patients with Previously Treated Non-Squamous NSCLC

Protocol Alliance A171901
Cancer Type: Older Non-Small Lung Cancer
Fast Facts

Older Non-Small Lung Cancer Patients (>/= 70 Years of Age) Treated with First-Line MK-3475 (Pembrolizumab) +/- Chemotherapy (Oncologist’s/Patient’s Choice)

Protocol SWOG S1900E
Cancer Type: NS NSCLC
Fast Facts

A Phase II Study of AMG 510 in Participants with Previously Treated Stage IV or Recurrent KRAS G12C Mutated Non-Squamous Non-Small Cell Lung Cancer (ECOG-ACRIN Lung-MAP Sub-Study

Protocol SWOG S1800D
Cancer Type: Stage IV or Recurrent Non-Small Cell Lung Cancer
Fast Facts

A Phase 11/111 Study of N-803 (ALT-803) plus Pembrolizumab versus Standard of Care in Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer Previously Treated with Anti-PD-1 or Anti-PD-L 1 Therapy (Lung-MAP Non-Match Sub-Study)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1827
Cancer Type: Small Cell Lung
Fast Facts

MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI):  A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

Protocol NRG LU007
Cancer Type: ES-SCLC
Fast Facts

 RAndomized Phase II/III Trial Of Consolidation Radiation + Immuno-therapy for ES-SCLC:  RAPTOR trial

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG LU006
Cancer Type: MALIGNANT PLEURAL MESOTHELIOMA

PHASE III RANDOMIZED TRIAL OF PLEURECTOMY/DECORTICATION PLUS
CHEMOTHERAPY WITH ORWITHOUT ADJUVANT HEMITHORACIC
INTENSITY-MODULATED PLEURAL RADIATION THERAPY (IMPRINT)
FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol PDM 9846
Cancer Type: Tissue Procurement
Fast Facts

Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A151216
Cancer Type: Non-Small Cell Lung
Fast Facts

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Sub-Studies to ALCHEMIST: A081105,  E4512 and EA5142

Protocol LUNG MAP
Cancer Type: NSCLC
Fast Facts

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

Please check out the rare protocol list to locate other studies within this disease site.

Lymphoma

Protocol Alliance A051301
Cancer Type: Lymphoma
Fast Facts

A Randomized Double-Blind Phase III Study of Ibrutinib During and Following Autologous Stem Cell Transplantation Versus Placebo in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype

Protocol Alliance A051701
Cancer Type: Double-hit and double-expressing lymphomas
Fast Facts

Randomized Phase II/III Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1608
Cancer Type: FOLLICULAR LYMPHOMA
Fast Facts

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA4181
Cancer Type: Untreated Mantle Cell lymphoma
Fast Facts

A Randomized 3-Arm Phase II Study Comparing 1.) Bendamustine, Rituximab and High Dose Cytarabine (BR/CR) 2.) Bendamustine, Rituximab, High Dose Cytarabine and Acalabrutinib (BR/CR-A), and 3.) Bendamustine, Rituximab and Acalabrutinib (BR-A) in Patients <70 years old with Untreated Mantle Cell Lymphoma 

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1925
Cancer Type: CLL/SLL
Fast Facts

RANDOMIZED, PHASE III STUDY OF EARLY INTERVENTION WITH VENETOCLAX AND OBINUTUZUMAB VERSUS DELAYED THERAPY WITH VENETOCLAX AND OBINUTUZUMAB IN NEWLY DIAGNOSED ASYMPTOMATIC HIGH-RISK PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): EVOLVE CLL/SLL STUDY

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1826
Cancer Type: ADVANCED STAGE CLASSICAL HODGKIN LYMPHOMA
Fast Facts

A Phase III, Randomized Study of Nivolumab (Opdivo) Plus AVD or Brentuximab Vedotin (Adcetris) Plus AVD in Patients (Age >/= 12 Years) with Newly Diagnosed Advanced Stage Classical Hodgkin Lymphoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG ANHL1931
Cancer Type: Lymphoma
Fast Facts

COG ANHL1931

A Randomized Phase 3 trial of Nivolumab (NSC#748726 IND#125462) in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

This is an AYA protocol  ≥ 2 years

Please check out the rare protocol list to locate other studies within this disease site.

Multisite

Protocol URCC 18007
Cancer Type: Cancer-Related Fatigue
Fast Facts

Randomized Placebo-Controlled Trial of Bupropion for Cancer-Related Fatigue

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EAY131 - MATCH
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH)

Protocol EAY131 - MATCH Protocol H
Cancer Type: Molecular
Fast Facts

Molecular Analysis for Therapy Choice (MATCH): MATCH Treatment Subprotocol H: EAY131-H: Phase II Study of Dabrafenib and Trametinib in Patients with Tumors with BRAF V600E or V600K Mutations (Excluding Melanoma and Thyroid Cancer)

Protocol EAY131 - MATCH Protocol Z1M
Cancer Type: Molecular
Fast Facts

Phase 2 Study of Nivolumab and BMS-986016 (Relatlimab) in Patients with LAG-3+ Tumors with Mismatch Repair Deficiency (MMR-d) after Progression on Anti-PD-1/PD-L1 Therapy

Protocol TAPUR
Cancer Type: Multisite
Fast Facts

Targeted Agent and Profiling Utilization Registry (TAPUR) Study

Protocol SWOG S1609 DART
Cancer Type: Rare Tumors
Fast Facts

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Protocol COG ADVL1823
Cancer Type: multisite
Fast Facts

COG-ADVL1823: Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias
Patients must be ≤ 30 years of age at the time of study entry

Temporarily Closed to Accrual

Please check out the rare protocol list to locate other studies within this disease site.

Protocol 10323 Moonshot
Cancer Type: Biospecimen
Fast Facts

Cancer Moonshot Biobank Research Protocol

Please check out the rare protocol list to locate other studies within this disease site.

Protocol DCP-001
Cancer Type: Multisite - Screening

Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG ALTE2031
Cancer Type: multisite
Fast Facts

ALTE2031 - StepByStep: A Randomized Trial of a Mobile Health and Social Media Physical Activity Intervention among Adolescent and Young Adult Childhood Cancer Survivors

Patient must be ≥15 years and < 21 years at the time of enrollment.

Protocol COG AGCT1531
Cancer Type: Germ Cell
Fast Facts

A Phase III Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients With Germ Cell Tumors

Age:

Low Risk Stratum (Stage I Ovarian Immature Teratoma and Stage I Malignant GCT (all sites))
Patients must be < 50 Years of Age at Enrollment.

Standard Risk 1
Patient must be < 11 Years of Age at Enrollment.

Standard Risk 2 & AYA-HEARS
Patients must be ≥ 11 and < 25 Years of Age at Enrollment. 

Protocol COG APEC14B1
Cancer Type: All patients
Fast Facts

The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study

Subjects must be ≤ 25 Years of Age at Time of Original Diagnosis, except for Patients who are being Screened Specifically for Eligibility onto a COG (or COG Participating NCTN) Therapeutic Study, for whom there is a Higher Upper Age Limit.

Protocol COG ALTE03N1
Cancer Type: Multi-site Cancer Control
Fast Facts

Key Adverse Events After Childhood Cancer

Diagnosis of Primary Cancer at Age 21 or Younger, Irrespective of Current Age.

Protocol COG ALTE05N1
Cancer Type: Multisite Long Term Follow-up
Fast Facts

Umbrella Long-Term Follow-Up Protocol

Only Available to Patients Already Enrolled on a COG Intervention Protocol.

Protocol COG ALTE07C1
Cancer Type: Multi-Site Cancer Control
Fast Facts

Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer

Protocol COG APEC1621 – MATCH Protocol SC
Cancer Type: Screening
Fast Facts

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

 

Protocol COG APEC1621 - MATCH
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Master Version Control Protocol

Protocol COG APEC1621 - MATCH Protocol A
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LOXO-101 (larotrectinib) in patients with tumors harboring actionable NTRK fusions.

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol B
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of JNJ-42756493 (Erdafitinib) in patients with tumors harboring FGFR1/2/3/4 alterations.

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol D
Cancer Type: Molecular

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of LY3023414 in Solid Tumors

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol F
Cancer Type: Molecular

COG APEC1621F

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II subprotocol of Ensartinib in patients with tumors harboring ALK or ROS1 genomic alterations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Temporary Closed to Accrual 11/1/2022

Protocol COG APEC1621 - MATCH Protocol K
Cancer Type: Molecular

APEC1621K - NCI-COG Pediatric Molecular Analysis for Therapy Choice MATCH - Phase 2 Subprotocol of AG-120 (Ivosidenib) in Patients with Tumors Harboring IDH1 Mutations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol M
Cancer Type: Molecular

APEC1621M: NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase 2 subprotocol of Tipifarnib in patients with tumors harboring HRAS genomic alterations

Patients must be ≥ 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG APEC1621 - MATCH Protocol N
Cancer Type: Molecular

APEC1621N: NCI-COG Pediatric Molecular Analysis for Therapy Choice (MATCH) – Phase 2 Subprotocol of LOXO-292 in Patients Harboring RET Gene Alterations

Patients must be ≥ than 12 months and ≤ 21 years of age at the time of study enrollment.

Protocol COG ARST1921
Cancer Type: Other
Fast Facts

COG-ARST1921: A Safety, Pharmacokinetic and Efficacy Study of a Gamma-Secretase Inhibitor, Nirogacestat (PF-03084014; IND# 146375), in Children and Adolescents with Progressive, Surgically Unresectable Desmoid Tumors

Protocol COG ACCL21C2
Cancer Type: Multi-site Cancer Control
Fast Facts

COG-ACCL21C2: Prospective Cohort Study to Evaluate Immunologic Response Following COVID-19 Vaccination in Children, Adolescents and Young Adults with Cancer

≥6 months and ≤37 years of age at time of enrollment

Please check out the rare protocol list to locate other studies within this disease site.

Myeloma

Protocol EAA181
Cancer Type: Newly diagnosed Multiple Myeloma
Fast Facts

Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EAA173
Cancer Type: Smoldering Myeloma
Fast Facts

Daratumumab to Enhance Therapeutic Effectiveness of Revlimid in Smoldering Myeloma (DETER-SMM)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EAA171
Cancer Type: Myeloma - MRD Assessment
Fast Facts

Optimizing Prolonged Treatment In Myeloma Using MRD Assessment (OPTIMUM)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1803
Cancer Type: Multiple Myeloma
Fast Facts

Phase III Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study)

Please check out the rare protocol list to locate other studies within this disease site.

Neuroblastoma

Protocol COG ANBL00B1
Cancer Type: Neuroblastoma-Biology
Fast Facts

Neuroblastoma Biology Studies

All Newly Diagnosed Patients with Suspected Neuroblastoma, Suspected Ganglioneuroblastoma, or Suspected Ganglioneuroma/Maturing Subtype Seen at COG Institutions are Eligible for this Study. 

Protocol COG ANBL1232
Cancer Type: NBL
Fast Facts

Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-High-Risk Neuroblastoma

TEMPORARY CLOSURE for Group C (Groups A1 and B Remain Open)

Protocol COG ANBL1531
Cancer Type: High-Risk Neuroblastoma
Fast Facts

A Phase III Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children With Newly Diagnosed High-Risk Neuroblastoma (NBL)

Age - Patient must be ≥ 365 Days and ≤ 30 Years of Age at Diagnosis.

ARM C perm closed

Protocol COG ANBL1821
Cancer Type: Neuroblastoma
Fast Facts

A Phase 2 Randomized Study of Irinotecan/Temozolomide/Dinutuximab with or without Eflornithine (DFMO) (IND# 141913) in Children with Relapsed, Refractory or Progressive Neuroblastoma

 

Patients ≥ 1 year of age at the time of enrollment are eligible for this study.

Please check out the rare protocol list to locate other studies within this disease site.

Rare

Protocol SWOG S1706
Cancer Type: Inflammatory Breast Cancer

A Phase II Randomized Trial of Olaparib (NSC-747856) Administered Concurrently with Radiotherapy versus Radiotherapy Alone for Inflammatory Breast Cancer

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A021804
Cancer Type: ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

A PROSPECTIVE, MULTI-INSTITUTIONAL PHASE II TRIAL EVALUATING TEMOZOLOMIDE VS. TEMOZOLOMIDE AND OLAPARIB FOR ADVANCED PHEOCHROMOCYTOMA AND PARAGANGLIOMA

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A091902
Cancer Type: ANGIOSARCOMA

A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAÏVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA

Please check out the rare protocol list to locate other studies within this disease site.

Protocol SWOG S1922
Cancer Type: Small bowel Adenocarcinoma

Randomized Phase II Selection Study of Ramucirumab and Paclitaxel versus FOLFIRI in Refractory Small Bowel Adenocarcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A031702
Cancer Type: rare genitourinary tumors

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA3163
Cancer Type: Nasal and Paranasal Sinus Squamous Cell Carcinoma

Phase II Randomized Trial of Neo-Adjuvant Chemo f/b Surgery and Post-Op Radiation vs Surgery and Post-Op Radiation for Organ Preservation of T3 and T4a Nasal and Paranasal Sinus Squamous Cell Carcinoma (NPNSCC)

Protocol NRG HN001
Cancer Type: Nasopharyngeal Carcinoma

Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)

Please check out the rare protocol list to locate other studies within this disease site.

Protocol NRG LU006
Cancer Type: MALIGNANT PLEURAL MESOTHELIOMA

PHASE III RANDOMIZED TRIAL OF PLEURECTOMY/DECORTICATION PLUS
CHEMOTHERAPY WITH ORWITHOUT ADJUVANT HEMITHORACIC
INTENSITY-MODULATED PLEURAL RADIATION THERAPY (IMPRINT)
FOR MALIGNANT PLEURAL MESOTHELIOMA (MPM)

Please check out the rare protocol list to locate other studies within this disease site.

Sarcoma

Protocol Alliance A091902
Cancer Type: ANGIOSARCOMA

A MULTICENTER PHASE II TRIAL OF PACLITAXEL WITH AND WITHOUT NIVOLUMAB IN TAXANE NAÏVE, AND NIVOLUMAB AND CABOZANTINIB IN TAXANE PRETREATED SUBJECTS WITH ANGIOSARCOMA

Please check out the rare protocol list to locate other studies within this disease site.

Protocol COG ARST1431
Cancer Type: IR Rhabdomyosarcoma
Fast Facts

A Randomized Phase III Study of Vincristine, Dactinomycin, Cyclophosphamide (VAC) Alternating With Vincristine and Irinotecan (VI) Versus VAC/VI Plus Temsirolimus (TORI, Torisel, NSC# 683864) in Patients With Intermediate Risk (IR) Rhabdomyosarcoma (RMS)

Feasibility Phase: Patients must be < 21 Years of Age at the Time of Enrollment.
Efficacy Phase: Patients must be ≤ 40 Years of Age at the Time of Enrollment.

Protocol COG-ARST2031
Cancer Type: High Risk Rhabdomyosarcoma (HR-RMS)
Fast Facts

COG ARST2031

A Randomized Phase 3 Trial of Vinorelbine, Dactinomycin, and Cyclophosphamide (VINO-AC) Plus Maintenance Chemotherapy with Vinorelbine and Oral Cyclophosphamide (VINO-CPO) vs Vincristine, Dactinomycin and Cyclophosphamide (VAC) plus VINO-CPO Maintenance in Patients with High Risk Rhabdomyosarcoma (HR-RMS)

Patients must be ≤ 50 years of age at the time of enrollment.

Protocol COG ARST2032
Cancer Type: Rhabdomyosarcoma
Fast Facts

COG- ARST2032: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma

Patients must be ≤ 21 years at the time of enrollment.

Protocol COG AOST2031
Cancer Type: Osteosarcoma
Fast Facts

COG AOST2031

A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma

Patients must be < 50 years at the time of enrollment

Please check out the rare protocol list to locate other studies within this disease site.

Skin

Protocol ECOG EA6141
Cancer Type: Melanoma-unresectable
Fast Facts

Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma

Protocol EA6192
Cancer Type: Advanced Melanoma
Fast Facts

A Phase II Study of Biomarker Driven Early Discontinuation of anti-PD-1 Therapy in Patients with Advanced Melanoma (PET-Stop)

Protocol SWOG S2000
Cancer Type: Melanoma with Brain Metastases
Fast Facts

A Randomized Phase 2 Trial Of Encorafenib + Binimetinib + Nivolumab Vs Ipilimumab + Nivolumab In Brafv600-Mutant Melanoma with Brain Metastases

Protocol EA6194
Cancer Type: Operable Melanoma
Fast Facts

Phase II Randomized Study of Neoadjuvant Pembrolizumab Alone or in Combination with CMP-001 in Patients with Operable Melanoma: Efficacy and Biomarker Study

Protocol SWOG S2015
Cancer Type: primary cutaneous melanoma
Fast Facts

Melanoma Margins Trial (MelMarT-II): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma

Protocol Alliance A091903
Cancer Type: RESECTED MUCOSAL MELANOMA
Fast Facts

A RANDOMIZED PHASE II TRIAL OF ADJUVANT NIVOLUMAB WITH OR WITHOUT CABOZANTINIB IN PATIENTS WITH RESECTED MUCOSAL MELANOMA

Please check out the rare protocol list to locate other studies within this disease site.

Protocol EA6174
Cancer Type: Merkel Cell Carcinoma
Fast Facts

A Phase III Randomized Trial Comparing Adjuvant MK-3475 (Pembrolizumab) to Standard of Care Observation in Completely Resected Merkel Cell Carcinoma

Please check out the rare protocol list to locate other studies within this disease site.

Protocol Alliance A091802
Cancer Type: Carcinoma of the Skin
Fast Facts

Phase II Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma of the Skin 

Please check out the rare protocol list to locate other studies within this disease site.

Cancer clinical trials are research studies for developing better ways of detecting, treating, and eventually preventing cancer. By taking part in a clinical trial, you are among the first to receive new research treatments before they are widely available. Your participation in a clinical trial will influence the future direction of cancer care.

If you are interested in participating in a clinical trial, consult with your physician. Please note: clinical trials are not risk free. Patients must explore the options that are best for their individuals needs with the help of their physician.